Evaluation of effects of Persian Gulnar on bleeding in patients with leiomyoma of uterus

Evaluation of effects of Punica granatum L.(Persian Gulnar) on bleeding in patients with leiomyoma of uterus (in Iranian Traditional Medicine)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013120715703N1

Enrollment

Registered

2014-02-12

Start date

2014-02-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Leiomyoma of uterus. Leiomyoma of uterus

Interventions

Intervention 1: Medication administration to patient (Persian Gulnar syrup, 5 cc three times a day) in menstrual cycle. Intervention time: Three months (each month 7 days). Intervention 2: Placebo adm

Treatment - Drugs

Placebo

Medication administration to patient (Persian Gulnar syrup, 5 cc three times a day) in menstrual cycle. Intervention time: Three months (each month 7 days).

Placebo administration to patients in menstrual cycle. ( 5 cc three times a day) Intervention Time: Two months (each month 7 days).

Eligibility

Sex/Gender

Female

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1) Age: 18-50 years 2) Ultrasound evidence of uterine leiomyoma (submucosal leiomyoma, intramural leiomyoma, subserosal leiomyoma). 3) History of abnormal menstrual bleeding based on the patient's complaint. Exclusion Criteria 1) Indication of uterine surgery (except Caesarean section or cervical conization). 2) Patients receiving progesterone, acetyl salicylic acid anticoagulant. 3) Patients with a positive pregnancy test. 4) History of allergy to Persian Gulnar. 5) Known hemoglobinopathies. 6) Known severe coagulation disorder. 7) Patients receiving Anti-fibrinolytic. 8) Hemoglobin below 9.5. 9) Ultrasound evidence of hyperplasia of the endometrium.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Menstrual blood volume. Timepoint: Before the intervention, weeks 5, 9, 13 after intervention. Method of measurement: Pictorial Blood Loss assessment Chart (PBAC).;Quality of life that is evaluated by Menorrhagia Questionnaire (MQ). Timepoint: Before the intervention, weeks 13 after intervention. Method of measurement: Quality of life that is evaluated by Menorrhagia Questionnaire (MQ).;The size of leiomyoma. Timepoint: Before the intervention, weeks 13 after intervention. Method of measurement: ultrasound.	—

Measure

Time frame

Menstrual blood volume. Timepoint: Before the intervention, weeks 5, 9, 13 after intervention. Method of measurement: Pictorial Blood Loss assessment Chart (PBAC).;Quality of life that is evaluated by Menorrhagia Questionnaire (MQ). Timepoint: Before the intervention, weeks 13 after intervention. Method of measurement: Quality of life that is evaluated by Menorrhagia Questionnaire (MQ).;The size of leiomyoma. Timepoint: Before the intervention, weeks 13 after intervention. Method of measurement: ultrasound.

—

Secondary

Measure	Time frame
Side effects. Timepoint: weeks 5, 9, 13 after intervention. Method of measurement: Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHajar Memarzadeh zavareh

School of Traditional Medicine Traditional Medicine and Materia Medica Research Center Shahid Behesh

hajarmemarzadeh@sbmu.ac.ir hajarmemarzadeh@gmail.com hajarmemarzadeh@yahoo.com+98 21887735212

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026